Mather Group LLC. Raises Stock Holdings in Danaher Co. (NYSE:DHR)

Mather Group LLC. lifted its stake in Danaher Co. (NYSE:DHR) by 155.8% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,182 shares of the conglomerate’s stock after acquiring an additional 4,984 shares during the quarter. Mather Group LLC.’s holdings in Danaher were worth $2,043,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in DHR. Vanguard Group Inc. boosted its stake in shares of Danaher by 7.4% during the 1st quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock worth $15,009,928,000 after acquiring an additional 4,163,657 shares during the last quarter. Wellington Management Group LLP lifted its position in Danaher by 12.0% during the fourth quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock valued at $6,460,966,000 after purchasing an additional 2,998,161 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Danaher by 10.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock valued at $3,876,694,000 after purchasing an additional 1,619,586 shares during the period. Capital International Investors increased its position in Danaher by 9.1% in the fourth quarter. Capital International Investors now owns 15,956,519 shares of the conglomerate’s stock worth $3,691,735,000 after buying an additional 1,334,781 shares in the last quarter. Finally, Norges Bank bought a new position in shares of Danaher in the fourth quarter worth about $1,752,382,000. Institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling at Danaher

In related news, Director Linda Filler sold 3,928 shares of the business’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.50, for a total value of $1,097,876.00. Following the completion of the sale, the director now owns 41,149 shares of the company’s stock, valued at approximately $11,501,145.50. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Danaher news, Director Linda Filler sold 3,928 shares of Danaher stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.50, for a total transaction of $1,097,876.00. Following the sale, the director now owns 41,149 shares of the company’s stock, valued at approximately $11,501,145.50. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Matthew Mcgrew sold 46,377 shares of the stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $253.05, for a total transaction of $11,735,699.85. Following the completion of the sale, the chief financial officer now owns 29,407 shares of the company’s stock, valued at $7,441,441.35. The disclosure for this sale can be found here. Over the last three months, insiders have sold 113,174 shares of company stock valued at $29,775,644. Company insiders own 11.10% of the company’s stock.

Danaher Stock Down 0.2 %

Danaher stock traded down $0.48 during midday trading on Tuesday, reaching $268.84. The company’s stock had a trading volume of 2,763,612 shares, compared to its average volume of 2,909,858. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70. The stock has a market capitalization of $194.16 billion, a P/E ratio of 46.18, a PEG ratio of 4.62 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The stock’s 50-day simple moving average is $256.42 and its 200-day simple moving average is $251.43.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter last year, the business posted $2.05 EPS. The firm’s quarterly revenue was down 2.9% on a year-over-year basis. On average, sell-side analysts expect that Danaher Co. will post 7.59 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on DHR. Stifel Nicolaus raised their price target on Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. SVB Leerink lifted their price objective on shares of Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. Citigroup increased their price objective on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Finally, HSBC raised Danaher from a “hold” rating to a “buy” rating and lifted their target price for the stock from $250.00 to $280.00 in a report on Wednesday, April 17th. Six research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $276.88.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.